Glytec Glucommander
by Glytec, LLC
· Based in United States →
— Stopping Preventable Harm. Backed by Over 20 Years of Proven Outcomes.
Contact glytec for pricing details.
Regulatory Status Disclosed
Overview
GlytecOne is a unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence. It connects care team members and hospital leaders with data and tools to deliver safer, more consistent glucose management across health systems. Glytec’s eGlycemic Management System (eGMS) centers on Glucommander, an FDA-cleared, cloud-based software that provides personalized insulin dosing recommendations for both IV and subcutaneous insulin therapy in hospitals and health systems. It helps hospitals standardize metabolic care, surface risk before it becomes harm, and prove measurable outcomes. GlytecOne also helps health plans close the metabolic care gap for inpatient and post-discharge to close Stars and HEDIS measure gaps for health plan members.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- FDA-cleared insulin dosing guidance (IV and SubQ)
- Personalized insulin dosing recommendations
- EHR integration (Epic, Cerner, Meditech, and others)
- Clinical decision support and workflow automation
- Real-time patient visibility and structured clinical review (Command Center)
- Enterprise analytics, benchmarking, and eCQM-aligned reporting
- Population health intelligence for glycemic management
- Safety guardrails and alerts (e.g., glucose velocity warnings)
- Automated data import and single sign-on
- Support for complex conditions like DKA and HHS
Use Cases
- Standardizing metabolic care in hospitals
- Reducing severe hypoglycemia and hyperglycemia events
- Decreasing hospital length of stay
- Lowering 30-day readmission rates for patients with diabetes
- Improving compliance with glycemic control quality measures (CMS eCQMs)
- Optimizing insulin therapy across the continuum of care (inpatient to outpatient)
What Physicians Need to Know
Evidence Base (guidelines, literature scope)
Glytec Glucommander is an FDA-cleared, algorithm-driven insulin dosing software that replaces traditional sliding scale insulin therapy and paper protocols. [1, 19, 30] It is supported by over 100 peer-reviewed publications and 100 patents. [11] The system provides personalized insulin dosing recommendations based on real-time and historical patient data, learning each patient's insulin sensitivity. [1, 3] It aligns with guidelines from leading organizations like the American Diabetes Association (ADA) for inpatient glycemic management, advocating for safe IV insulin use in critically ill patients and basal-bolus therapy for non-ICU patients. [27, 34]
Clinical Validation Studies
Numerous studies validate Glucommander's safety and efficacy. [18] Hospitals using Glucommander have reported a reduction in severe hypoglycemia by up to 73% (and 99.8% reduction in severe hypoglycemia in some cases), a decrease in length of stay by up to 3.2 days, and lower 30-day readmission rates for patients with diabetes. [2, 19, 30] One study showed a 98% reduction in severe hypoglycemia (<70 mg/dL) at Grady Health System. [23, 25] In a study of DKA patients, Glucommander achieved equally rapid glycemic control and acidosis correction with less intravenous insulin and shorter PICU and hospital stays compared to manual infusion. [15] Another study demonstrated improved Time-in-Range (TIR) from 48.0% to 73.8% in Type 2 Diabetes patients using Glucommander with CGM data. [12] A multi-center retrospective study involving 1,750 DKA patients across 34 medical centers found optimal outcomes with a specific initial multiplier and glucose target range, with a total of 7.9% of patients experiencing hypoglycemia. [24]
Alert Fatigue Management
Glucommander helps reduce alert fatigue by providing data through predefined criteria, delivering meaningful information rather than generic notifications. [9] It includes safety features like glucose velocity warnings, alerting nurses to sudden drops in blood glucose to prevent hypoglycemia. [1, 6, 20] The system also dynamically adjusts the next blood glucose check based on patient values and trends. [1]
Override Rate Data
While specific override rate data is not explicitly provided, Glytec emphasizes that clinicians review and confirm all insulin dosing recommendations generated by Glucommander. [4, 9, 14, 21, 23] This indicates that the system provides decision support, but the final decision rests with the healthcare professional.
Drug Interaction Checking
Glucommander is designed to adjust insulin dosing recommendations based on changes in patient condition and medications. [20] While not explicitly detailed as a comprehensive drug interaction checker, it acknowledges the impact of other medications, such as steroids, on blood glucose levels. [20]
Differential Diagnosis Support
Glucommander is a specialized tool for glycemic management and insulin dosing, not a general diagnostic tool. [9] Its primary function is to provide personalized insulin recommendations for patients with hyperglycemia, including those with conditions like diabetic ketoacidosis and hyperosmolar hyperglycemic state. [6, 16, 32]
Guideline Update Frequency
Glytec's solutions are continuously updated, with the latest version of Glucommander (3.5.3.0) supporting Epic's latest Hyperspace client as of August 2023. [8] The company also references alignment with annual updates to guidelines such as the ADA Standards of Care in Diabetes. [27]
Clinical Workflow Integration
Glucommander is designed for seamless integration with existing EHR systems, including Epic, Cerner (Oracle Health), and Meditech, via bi-directional interoperability. [2, 7, 8, 11, 14, 32] This allows for automated import of patient information and lab results (ADT, LIS), single sign-on (SSO), and automated documentation of clinician-confirmed dosing decisions back into the EHR. [6, 7, 10, 14, 22] It provides a guided workflow, safety alerts, and surveillance, reducing manual data entry, charting time, and transcription errors. [5, 6, 7, 9, 22] GlucoView and GlucoSurveillance modules offer dashboards for patient glucose status, next BG check reminders, and identification of at-risk patients. [1, 3, 22]
Decision Audit Trail
GlytecOne includes built-in audit trails and documentation support, logging every dosing decision and pharmacist review. [4, 7, 14, 17, 21] This ensures that all glycemic management decisions are defensible and traceable, supporting medication safety reviews, Joint Commission preparation, and regulatory compliance. [4, 14, 21]
Physician Tip
Glucommander is an FDA-cleared, algorithm-driven tool that provides personalized insulin dosing recommendations for both IV and subcutaneous insulin therapy in adult and pediatric patients (ages 2 and above). [1, 4, 20, 32, 35] It is designed to reduce hypoglycemia and hyperglycemia, decrease length of stay, and lower readmission rates. [2, 5, 19, 30] Remember that while the software provides evidence-based recommendations, the final clinical decision and confirmation of dosing remain with the healthcare professional. [4, 9, 14, 21, 23] Leverage its seamless EHR integration to streamline workflows and reduce manual tasks, allowing more focus on patient care. [6, 7, 9, 22] Utilize the surveillance and analytics tools (GlucoSurveillance, GlucoView, GlucoMetrics) for proactive patient monitoring, care coordination, and performance tracking. [1, 3, 16, 22]
Glytec Glucommander offers robust bi-directional integration with major EHR systems, including Epic, Oracle Health (Cerner), and Meditech. [2, 7, 8, 11, 14, 32] This integration facilitates automated data exchange for patient demographics (ADT), lab results (LIS), insulin orders, and medication administration records (MAR), minimizing manual entry and transcription errors. [7, 10] Single sign-on (SSO) capability further enhances workflow efficiency. [6, 7] The platform is EHR-agnostic and can integrate with any EHR system. [10]
Details
| Category | Clinical Decision Support & Reference, Endocrinology & Metabolic AI, Pharmacology & Dosing AI |
| Pricing | Contact glytec for pricing details. |
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Critical Care, Endocrinology, Hospital Medicine |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Glytec Glucommander
Press & Coverage
Glytec Press Release
Glytec Simplifies Glycemic Management for Clinicians and Pharmacists with New Glucommanderu00ae Enhancements
Glytec unveiled the latest version of its Glucommanderu00ae insulin dosing software, featuring enhancements that streamline workflows, improve patient outcomes, and offer tighter support for top electronic health record (EHR) systems. These innovations make personalized care easier for providers, nurses, and pharmacists.
2023-08
Glytec Press Release
KLAS Recognizes Glytec Glucommanderu00ae for Advancing Inpatient Glycemic Management
A new KLAS First Look report highlights that hospitals using Glytec's Glucommanderu00ae experienced fewer hypoglycemic events, improved insulin dosing accuracy, and enhanced patient safety. The report also noted Glucommander's effective EHR integration across major platforms.
2025-11
HLTH
Glytec Secures $36M to Advance AI-Powered Diabetes Care Platform
Glytec secured $36 million in growth investment to expand its AI-powered diabetes management platform, particularly its Glucommanderu00ae Software-as-a-Service solution. This funding will also accelerate the development of innovative technologies and support research and development initiatives.
2025-06
Glytec Press Release
Glytec Named Top Diabetes Management Platform for 2025
Healthcare Tech Outlook recognized Glytec as its Top Diabetes Management Platform for 2025, acknowledging its leadership in hospital insulin management, clinical outcomes, and enterprise scalability. Glucommander, an FDA-cleared insulin dosing software, is central to Glytec's cloud-based platform.
2025-09
Glytec Case Study
Subcutaneous Insulin Management: Baptist Health Results
A six-month study at Baptist Health found that patients managed with Glucommander SubQ achieved better glycemic control at discharge and lower rates of hypoglycemia, despite having significantly higher admission blood glucose levels than the standard care group.
2026-06
Glytec Press Release
The Final Countdown for New CMS Glycemic Measures: Glytec Prepares Hospitals and Health Systems with Proven, FDA-Cleared Technology Platform
Glytec is supporting U.S. hospitals in preparing for the upcoming CMS mandate on inpatient glycemic control reporting, which will require reporting of severe hypoglycemia and hyperglycemia as electronic clinical quality measures. Glytec's FDA-cleared Glucommanderu00ae solution is designed to help hospitals meet these new requirements.
2025-07
Glytec Blog
Glucommander: Your roadmap to reduced hospital readmission rates
This article highlights how Glytec's Glucommander, an FDA-cleared, cloud-based software, can help reduce hospital readmission rates by improving glycemic control and providing personalized IV and SubQ insulin dosing support.
2024-12
Journal of Pediatric Endocrinology and Metabolism
Evaluating the Safety and Efficacy of Glucommander, a Computer-based Insulin Infusion Method, in Management of Diabetic Ketoacidosis in Children
A retrospective chart review found that children with diabetic ketoacidosis managed with Glucommander achieved equally rapid glycemic control and correction of acidosis, used less intravenous insulin, and had shorter PICU and total hospital stays compared to those managed with manual insulin infusion.
2009-02
Videos
Product demos, reviews, and walkthroughs for Glytec Glucommander.
IntelliSource International Client Work: Glytec - Sentara, Webinar
IntelliSource International
Frequently Asked Questions
Glytec Glucommander is designed to integrate with electronic health records (EHRs) to streamline the management of insulin. Physicians typically input patient-up-to-date information, and the system provides individualized insulin dosing recommendations. The platform aims to reduce the burden of manual calculations and frequent blood glucose checks by offering proactive adjustments.
Clinical studies and real-world data have demonstrated Glytec Glucommander's effectiveness in maintaining glycemic control while minimizing the risk of hypoglycemia. The system's algorithm dynamically adjusts insulin doses based on patient response, which contributes to improved safety and tighter glucose management across diverse patient populations, including those in critical care and general medical-surgical units.
While highly effective, Glytec Glucommander may have limitations in specific scenarios, such as patients with extremely rare or complex metabolic conditions not accounted for in its algorithms. It also requires consistent and accurate data input for optimal performance. In situations where frequent and rapid changes in patient status make algorithmic predictions challenging, close clinical oversight remains crucial.
Glytec Glucommander differentiates itself through its individualized, real-time algorithmic adjustments for both intravenous and subcutaneous insulin. Physicians might choose it over other solutions due to its proven track record in reducing glycemic variability and its ability to adapt to changing patient needs, which can lead to better outcomes and reduced nursing burden compared to traditional protocols.
Glytec Glucommander aims to foster high physician compliance through clear, evidence-based recommendations and seamless EHR integration. The system provides alerts and notifications to guide timely interventions, and its user-friendly interface is designed to build physician confidence in the suggested insulin adjustments, ultimately promoting consistent application of the protocol for improved patient safety and glycemic control.
The cost of implementing Glytec Glucommander involves licensing fees and integration expenses, which can vary based on the size and complexity of the healthcare institution. However, studies often show a positive return on investment through reductions in hypoglycemia-related events, decreased lengths of hospital stay, and improved patient outcomes, leading to overall cost savings and enhanced quality of care.
Suggest an Edit → | Report an issue
| Last Verified: 2026-06-23 | First Added: 2026-06-23